Research graph
References from Fluorodeoxyglucose-PET in Myocardial Viability and Ischemic Heart Disease. Local targets link to admitted publications; unresolved targets remain external evidence.
Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction
10.1093/eurheartj/ehm355 · 2007 · External reference
Global, regional, and national burden of ischaemic heart disease from 1990 to 2021: a comprehensive analysis based on the global burden of disease study 2021
10.7189/jogh.15.04291 · 2025 · External reference
Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the global burden of disease 2010 study
10.1161/circulationaha.113.004042 · 2014 · External reference
Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology
10.1002/ejhf.1747 · 2020 · External reference
Myocardial stunning and hibernation revisited
10.1038/s41569-021-00506-7 · 2021 · External reference
SPECT and PET in ischemic heart failure
10.1007/s10741-017-9594-7 · 2017 · External reference
Positron emission tomography for the assessment of myocardial viability
1991 · External reference
Stunned and hibernating myocardium: where are we nearly 4 decades later?
10.1161/jaha.119.015502 · 2020 · External reference
The complex role of cardiovascular imaging in viability testing
10.1016/j.pcad.2024.12.008 · 2025 · External reference
Physiological implications of myocardial scar structure
10.1002/j.2040-4603.2015.tb00658.x · 2015 · External reference
Positron emission tomography for the assessment of myocardial viability
2005 · External reference
State of the art: imaging for myocardial viability: a scientific statement from the American heart association
10.1161/hci.0000000000000053 · 2020 · External reference
Evaluation of myocardial cell damage by In-111-monoclonal antimyosin antibodies in patients under chronic tricyclic antidepressant drug treatment
10.1161/01.cir.91.6.1619 · 1995 · External reference
Myocardial viability: survival mechanisms and molecular imaging targets in acute and chronic ischemia
10.1161/circresaha.116.307898 · 2017 · External reference
Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction
10.1161/circulationaha.105.541664 · 2006 · External reference
Biphasic response to dobutamine predicts improvement of left ventricular dysfunction after revascularization: correlation with positron emission and rest-redistribution 201Tl tomographies
10.1023/b:caim.0000004302.68305.80 · 2003 · External reference
Incremental value of strain rate analysis as an adjunct to wall-motion scoring for assessment of myocardial viability by dobutamine echocardiography: a follow-up study after revascularization
10.1161/circulationaha.104.489310 · 2005 · External reference
Echocardiography: past, present, and future
10.1161/circimaging.124.016517 · 2024 · External reference
Multidetector computed tomography in reperfused acute myocardial infarction. Assessment of infarct size and no-reflow in comparison with cardiac magnetic resonance imaging
10.1097/rli.0b013e318181c8dd · 2008 · External reference
Dynamic CT myocardial perfusion: the role of functional evaluation in the diagnosis of coronary artery disease
10.3390/jcm12227062 · 2023 · External reference
Dynamic CT myocardial perfusion imaging
10.1016/j.jcct.2019.09.003 · 2020 · External reference
Myocardial viability and long-term outcomes in ischemic cardiomyopathy
10.1056/nejmoa1807365 · 2019 · External reference
Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography
10.1161/01.cir.94.11.2712 · 1996 · External reference
Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates: feasibility and reliability for prediction of postrevascularization outcome of asynergic territories
10.1016/0735-1097(94)90110-4 · 1994 · External reference
Stunning, hibernation, and assessment of myocardial viability
10.1161/circulationaha.107.702993 · 2008 · External reference
Hibernating myocardium: diagnosis and patient outcomes
10.1016/j.cpcardiol.2007.04.001 · 2007 · External reference
Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium
10.1067/mcd.2001.109973 · 2001 · External reference
Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy
10.1016/j.jacc.2011.09.073 · 2012 · External reference
Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance: assessment of patients with suspected coronary artery disease
2006 · External reference
Myocardial first-pass perfusion cardiovascular magnetic resonance: history, theory, and current state of the art
10.1186/1532-429x-10-18 · 2008 · External reference
The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction
10.1056/nejm200011163432003 · 2000 · External reference
Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function
10.1161/hc3501.096798 · 2001 · External reference
Myocardial viability assessment in patients with highly impaired left ventricular function: comparison of delayed enhancement, dobutamine stress MRI, end-diastolic wall thickness, and TI201-SPECT with functional recovery after revascularization
10.1007/s00330-005-2653-9 · 2005 · External reference
CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials
10.1016/j.jcmg.2012.02.009 · 2012 · External reference
Machine learning-based interpretation of non-contrast feature tracking strain analysis and T1/T2 mapping for assessing myocardial viability
10.1038/s41598-024-85029-0 · 2025 · External reference
Comparative analysis of myocardial viability multimodality imaging in patients with previous myocardial infarction and symptomatic heart failure
10.3390/medicina58030368 · 2022 · External reference
Comparison of myocardial viability by cardiac magnetic resonance imaging and echocardiography in patients with myocardial infarction: an observational cross-sectional study
2025 · External reference
Quantification in cardiac MRI: advances in image acquisition and processing
10.1007/s10554-009-9571-x · 2010 · External reference
Viability assessment with MRI is superior to FDG-PET for viability: con
10.1007/s12350-010-9209-3 · 2010 · External reference
The role of imaging modalities in estimating myocardial viability: a narrative review
10.3390/jcm14155529 · 2025 · External reference
Clinical indications for positron emission tomography myocardial perfusion imaging and myocardial blood flow quantification: an American Society of Nuclear Cardiology position statement
10.1016/j.nuclcard.2025.102619 · 2026 · External reference
American Society of Nuclear Cardiology and Society of Nuclear Medicine and molecular imaging joint position statement on the clinical indications for myocardial perfusion PET
10.1007/s12350-016-0626-9 · 2016 · External reference
Hybrid PET/CT and PET/MR in coronary artery disease: an update for Clinicians, with insights into AI-Guided integration
10.3390/jcdd12090338 · 2025 · External reference
Cardiac PET/MRI: recent developments and future aspects
10.1053/j.semnuclmed.2024.05.007 · 2024 · External reference
Cardiac PET/CT for the evaluation of known or suspected coronary artery disease
10.1148/rg.315115056 · 2011 · External reference
MR/PET imaging of the cardiovascular system
10.1016/j.jcmg.2017.07.008 · 2017 · External reference
Myocardial viability testing to guide coronary revascularization
2018 · External reference
Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography
10.1016/0735-1097(92)90008-b · 1992 · External reference
F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2)
10.1016/j.jacc.2007.09.006 · 2007 · External reference
The role of cardiac PET in diagnosis and prognosis of ischemic heart disease: optimal modality across different patient populations
10.1007/s11883-023-01107-0 · 2023 · External reference
Myocardial utilization of carbohydrate and lipids
10.1016/0033-0620(72)90029-1 · 1972 · External reference
Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle
10.1146/annurev.ph.36.030174.002213 · 1974 · External reference
Targeted metabolic imaging to improve the management of heart disease
10.1016/j.jcmg.2011.11.009 · 2012 · External reference
Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution
1986 · External reference
ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures
10.1007/s12350-016-0522-3 · 2016 · External reference
How to prepare patients for fluorine-18 fluorodeoxyglucose positron emission tomography myocardial viability assessment
10.1016/j.nuclcard.2025.102480 · 2026 · External reference
Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography
1992 · External reference
A simplified intravenous glucose loading protocol for fluorine-18 fluorodeoxyglucose cardiac single-photon emission tomography
10.1007/s002590050154 · 1997 · External reference
18F-FDG PET in myocardial viability assessment: a practical and time-efficient protocol
10.2967/jnumed.121.262432 · 2022 · External reference
Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability
2003 · External reference
Acipimox-enhanced 18F-fluorodeoxyglucose positron emission tomography for characterizing and predicting early remodeling in the rat infarct model
10.1007/s10554-011-9983-2 · 2012 · External reference
Safety and feasibility of cardiac FDG SPECT following oral administration of acipimox, a nicotinic acid derivative: comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients
10.1067/mnc.2002.125391 · 2002 · External reference
Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association
10.1161/hc0402.102975 · 2002 · External reference
Practical guide for interpreting and reporting cardiac PET measurements of myocardial blood flow: an information statement from the American Society of Nuclear Cardiology, and the Society of Nuclear medicine and molecular imaging
10.2967/jnumed.121.261989 · 2021 · External reference
A reverse flow-metabolism mismatch pattern on PET is related to multivessel disease in patients with acute myocardial infarction
1999 · External reference
Reverse mismatch pattern in cardiac 18F-FDG viability PET/CT is not associated with poor outcome of revascularization: a retrospective outcome study of 91 patients with heart failure
10.1097/rlu.0000000000001312 · 2016 · External reference
Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis
10.1016/s0735-1097(02)01726-6 · 2002 · External reference
Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis
10.1016/s0002-8703(03)00428-9 · 2003 · External reference
Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis
10.1007/s12350-010-9226-2 · 2010 · External reference
Long-term Follow-Up of outcomes with F-18-Fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease
2016 · External reference
Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial
10.1016/j.jcmg.2009.02.017 · 2009 · External reference
18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial
10.2967/jnumed.109.065938 · 2010 · External reference
Coronary-artery bypass surgery in patients with ischemic cardiomyopathy
10.1056/nejmoa1602001 · 2016 · External reference
Coronary-artery bypass surgery in patients with left ventricular dysfunction
10.1056/nejmoa1100356 · 2011 · External reference
Myocardial viability and survival in ischemic left ventricular dysfunction
10.1056/nejmoa1100358 · 2011 · External reference
Alternative Imaging Modalities in ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial
10.1186/1745-6215-14-218 · 2013 · External reference
Viability and outcomes with revascularization or medical therapy in ischemic ventricular dysfunction
10.1001/jamacardio.2023.3803 · 2023 · External reference
F-18-FDG uptake is a reliable predictory of functional recovery of akinetic but viable infarct regions as defined by magnetic resonance imaging before and after revascularization
10.1016/j.mri.2003.07.006 · 2004 · External reference
Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol
10.1093/eurheartj/ehi747 · 2006 · External reference
PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake
2015 · External reference
2018 ESC/EACTS guidelines on myocardial revascularization
10.1093/eurheartj/ehy394 · 2019 · External reference
2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American college of Cardiology/American Heart Association Joint Committee on clinical practice Guidelines
2022 · External reference
PET-MRI of coronary artery disease
10.1002/jmri.28554 · 2023 · External reference
Hybrid PET/MR imaging of the heart: feasibility and initial results
10.1148/radiol.13130231 · 2013 · External reference
Prospective evaluation of 18f-fdg uptake in post-ischemic myocardium by simultaneous pet/mri as a prognostic marker of functional outcome
10.1161/circimaging.115.004316 · 2016 · External reference
Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions
10.1007/s00259-020-04877-w · 2020 · External reference
Downstream indication to revascularization following hybrid cardiac PET/MRI: preliminary results
10.1097/mnm.0000000000000680 · 2017 · External reference
Hybrid PET/CT and PET/MRI imaging of vulnerable coronary plaque and myocardial scar tissue in acute myocardial infarction
10.1007/s12350-017-0918-8 · 2018 · External reference
Applications of pet-mri in cardiovascular disorders
10.1016/j.cpet.2020.06.007 · 2020 · External reference
Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction
10.1161/circimaging.110.961854 · 2011 · External reference
Molecular imaging of the chemokine receptor CXCR4 after acute myocardial infarction
10.1016/j.jcmg.2015.09.008 · 2015 · External reference
The future of molecular imaging
10.1016/j.jcmg.2011.05.003 · 2011 · External reference
Artificial intelligence and cardiac PET/computed tomography imaging
10.1016/j.cpet.2021.06.011 · 2022 · External reference
PET-based artificial intelligence applications in cardiac nuclear medicine
10.4414/smw.2022.w30123 · 2022 · External reference
Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT
10.1007/s00259-021-05341-z · 2021 · External reference
A novel approach to identifying hibernating myocardium using radiomics-based machine learning
2024 · External reference
Low-dose PET image noise reduction using deep learning: application to cardiac viability FDG imaging in patients with ischemic heart disease
10.1088/1361-6560/abe225 · 2021 · External reference
Deep learning in quantitative PET myocardial perfusion imaging: a study on cardiovascular event prediction
10.1016/j.jcmg.2019.08.009 · 2020 · External reference
Evaluation of the diagnostic value of joint PET myocardial perfusion and metabolic imaging for vascular stenosis in patients with obstructive coronary artery disease
10.1007/s12350-020-02160-x · 2021 · External reference
Multiparametric cardiac 18F-FDG PET in humans: kinetic model selection and identifiability analysis
10.1109/trpms.2020.3031274 · 2020 · External reference
Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy
10.1007/s12350-018-1395-4 · 2020 · External reference
A methodology to measure glucose metabolism by quantitative analysis of PET images
10.1007/s41666-024-00172-7 · 2024 · External reference
Multiparametric cardiac 18F-FDG PET in humans: pilot comparison of FDG delivery rate with 82Rb myocardial blood flow
10.1088/1361-6560/ac15a6 · 2021 · External reference
New opportunities for nuclear cardiology with total-body positron emission tomography/computed tomography
10.1016/j.nuclcard.2026.102652 · 2026 · External reference
An optimized fast track protocol to enhance the image quality of 18F-FDG PET myocardial viability imaging in diabetic CAD patients: a randomized controlled trial
10.1007/s11307-025-02074-5 · 2026 · External reference
Feasibility and application of trimetazidine in 18F-FDG PET myocardial metabolic imaging of diabetic mellitus patients with severe coronary artery disease: a prospective, self-controlled study
10.1007/s12350-021-02749-w · 2022 · External reference
Tracers for cardiac imaging: targeting the future of viable myocardium
10.3390/pharmaceutics15051532 · 2023 · External reference
Emerging PET tracers in cardiac molecular imaging
10.1007/s40119-022-00295-1 · 2023 · External reference
Mechanism of uptake and retention of F-18 BMS-747158-02 in cardiomyocytes: a novel PET myocardial imaging agent
10.1016/j.nuclcard.2007.07.009 · 2007 · External reference
18F labeled myocardial perfusion PET: new precision in cardiac imaging
10.1016/j.tcm.2025.03.008 · 2025 · External reference
Flurpiridaz F18: a new era in nuclear cardiac imaging – the first FDA-approved radiotracer in 30 years
10.1097/ms9.0000000000004032 · 2025 · External reference
Stable delineation of the ischemic area by the PET perfusion tracer 18F-fluorobenzyl triphenyl phosphonium after transient coronary occlusion
10.2967/jnumed.110.085993 · 2011 · External reference
Can the promise of radionuclide cardiac innervation imaging be fulfilled?
10.1007/s12350-021-02866-6 · 2022 · External reference
Molecular imaging visualizes recruitment of inflammatory monocytes and macrophages to the injured heart
10.1161/circresaha.118.314030 · 2019 · External reference
Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
10.2967/jnumed.119.226993 · 2019 · External reference
